We define late-onset myasthenia gravis (LOMG) when symptoms appear at ≥65 years of age. There has been a continuous increase in the incidence of LOMG with a clear male predominance. Commonly, patients present with focal (ocular or bulbar) weakness. A high index of suspicion required to achieve early diagnosis and to improve prognosis. Management options include acetylcholinesterase inhibitors, steroids, and immunosuppressants. The most controversial issue in treatment is thymectomy, because not enough data are available. Successful treatment is associated with improved survival, and death is often secondary to comorbidities.
Download full-text PDF |
Source |
|---|---|
| http://dx.doi.org/10.1002/mus.23964 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Advances in Disease-Modifying Therapeutics for Chronic Neuromuscular Disorders.
Semin Respir Crit Care Med
December 2024
Department of Neurology and Rehabilitation Medicine, University of Cincinnati, Cincinnati, Ohio.
Neuromuscular disorders can cause respiratory impairment by affecting the muscle fibers, neuromuscular junction, or innervation of respiratory muscles, leading to significant morbidity and mortality. Over the past few years, new disease-modifying therapies have been developed and made available for treating different neuromuscular disorders. Some of these therapies have remarkable effectiveness, resulting in the prevention and reduction of respiratory complications.
View Article and Find Full Text PDF[Clinical and epidemiological characteristics of myasthenia in the Altai region].
Zh Nevrol Psikhiatr Im S S Korsakova
December 2024
Altai State Medical University, Barnaul, Russia.
Objective: To analyze the epidemiological and clinical characteristics of myasthenia gravis (MG) in the Altai region (AR).
Material And Methods: One hundred and twenty-two patients with a verified diagnosis of MG, living in the AR, took part in the study. To collect data, a questionnaire was developed, the data of which formed the basis for the study.
Aging and infectious diseases in myasthenia gravis.
J Neurol Sci
November 2024
Department of Neurology, Haukeland University Hospital, Bergen, Norway; Department of Clinical Medicine, University of Bergen, Bergen, Norway.
Over the past 120 years, mortality associated with myasthenia gravis (MG) has steadily decreased while the incidence of MG has increased. While mortality due to MG has been ≤5 % for at least the past 25 years, the prevalence of MG has increased. This increase in prevalence of MG may be due, in part, to improvements in diagnostics but also to an aging global population and immunosenescence as the largest increases in MG prevalence have been in patients ≥65 years old.
View Article and Find Full Text PDFChanges in Myasthenia Gravis Incidence in Denmark From 1985 to 2021: A Nationwide Population-Based Study.
Neurology
January 2025
From the Department of Neurology, Aarhus University Hospital, Denmark.
Background And Objectives: Previous studies on incident myasthenia gravis (MG) have shown inconsistent results. In this study, we determined the MG incidence rates (IRs) over a 36-year period to detect potential trends in MG incidence over time and for different age groups.
Methods: In this nationwide population-based study from 1985 to 2021, we identified patients aged 18 and older with a primary MG diagnosis in the Danish National Patient Registry.
A nationwide epidemiological study of myasthenia gravis in Turkey.
J Neurol
December 2024
Department of Neurology, Gulhane Medical Faculty, University of Health Sciences, Ankara, Turkey.
Background: Variable incidence and prevalence rates of myasthenia gravis (MG) have been reported over time from different geographical regions. We aimed to determine incidence and prevalence of MG in Turkey and contribute to the development of proper national health policies.
Methods: Patients with G70.
Want AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!